Does Humana Cover Forteo (Teriparatide)? A Complete Insurance Guide

What Is Forteo and Why Does It Matter for Osteoporosis?

Forteo is recombinant human parathyroid hormone 1-34 (teriparatide), the first anabolic agent approved by the FDA for osteoporosis in postmenopausal women, men with primary or hypogonadal osteoporosis, and patients on sustained glucocorticoid therapy. Unlike bisphosphonates, which slow bone resorption, teriparatide actively stimulates new bone formation. The FDA approved the original Eli Lilly product in November 2002 (accessdata.fda.gov) and the 24-month lifetime cap on use reflects early osteosarcoma signals seen in rat studies at supraphysiologic doses.

Teriparatide's clinical benefit is well-established. The key Fracture Prevention Trial (N=1,637 postmenopausal women with prior vertebral fracture) showed teriparatide 20 mcg/day reduced new vertebral fractures by 65% and non-vertebral fractures by 53% versus placebo over a median 19 months [1]. Lumbar spine bone-mineral density (BMD) increased 9.7% and femoral neck BMD 2.8% [1]. Those numbers explain why AACE guidelines designate teriparatide a first-line option in patients with very high fracture risk, defined as a prior hip or vertebral fracture, a T-score at or below -3.0, or a 10-year FRAX hip-fracture probability at or above 4.5% [2].

The annual direct cost of osteoporotic fractures in the United States exceeded $57 billion in 2018 and is projected to reach $95 billion by 2040 [3]. Preventing even one hip fracture per patient justifies the drug's cost for payers, which is a core argument physicians use when appealing Humana denials.

How Humana's Formulary System Works

Humana uses a tiered formulary structure across its Medicare Advantage (MA-PD), standalone Part D prescription drug plans (PDP), and employer/commercial lines. Each tier carries a different cost-sharing level.

Forteo and its generic equivalents almost always land on Tier 4 (preferred specialty) or Tier 5 (non-preferred specialty), which carry the highest member cost-sharing before deductibles and out-of-pocket limits apply [4]. Humana publishes plan-specific formularies annually at humana.com. Because formularies change each January 1, the tier assignment and prior-authorization (PA) requirements you see in November during open enrollment may differ from what applied the prior year.

Specialty drugs like Forteo are often managed through Humana's specialty pharmacy partner, Humana Specialty Pharmacy or CenterWell Pharmacy, rather than retail chains. Using an out-of-network specialty pharmacy can trigger higher cost-sharing or even a coverage denial on some plan designs. Confirming network status before the first fill saves significant money.

Under the Inflation Reduction Act, Medicare Part D enrollees now face a $2,000 annual out-of-pocket cap starting in 2025 [5]. For a patient with a $700/month Tier 5 copay, hitting that cap mid-year means the rest of the year is covered at $0 cost-share. This change materially improves affordability for Medicare patients on Forteo.

Prior Authorization Criteria Humana Typically Requires

Prior authorization is not optional on Humana plans for Forteo. Approval generally requires the prescribing physician to document all of the following.

Diagnosis confirmation. The patient must have a documented diagnosis of osteoporosis, not just osteopenia, confirmed by dual-energy X-ray absorptiometry (DXA) showing a T-score of -2.5 or below, or by a history of a low-trauma (fragility) fracture [6].

Failure or intolerance of a bisphosphonate. Most Humana plans require a trial of at least one oral bisphosphonate (alendronate or risedronate) for a minimum of 6 to 12 months before approving teriparatide. Documented intolerance (esophageal disease, jaw osteonecrosis, atypical femoral fracture) can satisfy this requirement without a completed trial [7].

No history of bone radiation or skeletal malignancy. The FDA label carries a boxed warning about osteosarcoma risk; Humana reflects this by excluding patients with prior radiation therapy to the skeleton or a history of bone metastases [8].

Prescriber specialty. Some Humana PA forms require the prescriber to be an endocrinologist, rheumatologist, or orthopedic surgeon, rather than a primary care physician, at least for the initial authorization.

24-month lifetime limit. Coverage approvals are typically issued in 6-month increments and capped at 24 cumulative months, mirroring the FDA label. Humana will not authorize a second lifetime course of teriparatide.

Submitting complete documentation from the start cuts the average PA processing time significantly. According to the American Journal of Managed Care, incomplete PA submissions account for 39% of initial denials for specialty osteoporosis drugs, a figure that drops to under 8% when structured clinical checklists are used [9].

Step Therapy: What You Must Try First

Step therapy (also called "fail first") is standard on Humana plans for teriparatide. The required sequence typically looks like this.

Step 1: An oral bisphosphonate, specifically alendronate 70 mg weekly or risedronate 35 mg weekly, for 6 to 12 months. These are generic and cost as little as $4/month at many pharmacies [10].

Step 2: If Step 1 fails due to side effects or continued fracture, a second-line option such as denosumab (Prolia) 60 mg every 6 months or zoledronic acid (Reclast) 5 mg IV annually may be required on some Humana plan designs before teriparatide is approved [11].

Step 3: Teriparatide (Forteo or approved generic) is authorized after documented failure or intolerance at earlier steps.

Exceptions exist. Patients with a T-score at or below -3.5, a vertebral compression fracture causing height loss, or two or more prior fragility fractures may qualify for a step-therapy exception that bypasses the bisphosphonate requirement. The AACE 2020 guidelines explicitly state that "for patients at very high risk of fracture, anabolic therapy should be considered as initial treatment" [2], and quoting this language in a PA request strengthens the clinical case considerably.

Teriparatide Generics and How They Affect Humana Coverage

The FDA approved the first teriparatide generic (Brixelle, from Alvogen) in June 2022, followed by additional ANDA approvals [12]. Generics are bioequivalent to Forteo and carry the same 20 mcg/day dosing in a prefilled pen device. Humana plans may preferentially cover a generic teriparatide over brand Forteo if both are on the formulary, meaning a PA for brand Forteo could be denied if the generic is available and the plan treats them as therapeutically interchangeable.

Prescribing the generic by its generic name (teriparatide injection 20 mcg/80 mcg per mL) rather than "Forteo" allows the pharmacy to dispense whatever version Humana covers at the lowest tier. If a patient or physician prefers brand Forteo for device-familiarity reasons, a non-preferred brand exception request can be submitted, though approval is not guaranteed and cost-sharing will likely remain at the higher tier.

Cost Scenarios Under Different Humana Plans

The actual out-of-pocket amount depends on the specific plan. Three representative scenarios illustrate the range.

Humana Medicare Advantage (MA-PD) with Specialty Tier Copay. A patient enrolled in a mid-tier Humana MA-PD plan might face a 33% coinsurance on Tier 5 drugs after meeting the plan deductible. At a $3,000/month list price, that is $990/month before reaching the $2,000 annual cap. After the cap, cost is $0 for the remainder of the calendar year [5].

Humana Part D Standalone PDP (e.g., Humana Premier Rx Plan). Formulary details vary by region, but specialty tier drugs often carry 25% to 33% coinsurance in the coverage gap. The 2025 $2,000 out-of-pocket cap applies here as well [5].

Humana Commercial/Employer Plan. Cost-sharing structures differ substantially. Some employer plans place specialty drugs on a separate "specialty formulary" with coinsurance ranging from 20% to 50%. Commercial patients are also eligible for Eli Lilly's LillyAnswers copay assistance card, which reduces monthly cost to as low as $25 for commercially insured patients who meet income criteria [13].

Medicare patients cannot use manufacturer copay cards. However, the Extra Help / Low Income Subsidy (LIS) program through Social Security may reduce Part D specialty drug costs to $11.20 or $0 per month for qualifying low-income enrollees in 2025 [14].

How to Appeal a Humana Denial for Forteo

Humana denies a meaningful portion of initial specialty drug PA requests. Federal regulations give Medicare enrollees specific appeal rights under 42 CFR Part 423 [15]. The sequence runs: coverage determination, redetermination (Humana internal review, 7-day standard or 72-hour expedited), Independent Review Entity (IRE) review, Office of Medicare Hearings and Appeals (OMHA), Medicare Appeals Council, and federal district court.

For commercial plans, state insurance law governs timelines, but most states require a decision within 30 days for standard appeals and 72 hours for urgent appeals.

A strong appeal includes the following specific documents.

1. The physician's clinical letter citing the AACE 2020 guideline recommendation for anabolic-first therapy in very high-risk patients [2].
2. The DXA report with actual T-scores and Z-scores.
3. Radiology reports documenting any prior vertebral or hip fractures.
4. Documentation of bisphosphonate failure, intolerance, or contraindication.
5. A FRAX calculation printout showing 10-year fracture probability.

The FRAX tool, validated in large cohorts and endorsed by the National Osteoporosis Foundation, calculates absolute fracture risk using age, sex, BMD, and clinical risk factors [16]. A FRAX hip probability at or above 3% or major osteoporotic fracture probability at or above 20% meets the National Osteoporosis Foundation threshold for pharmacologic treatment [16], and presenting this number makes denial harder to sustain.

The HealthRX clinical team uses a standardized PA submission framework for teriparatide that packages the DXA report, FRAX printout, fracture history, bisphosphonate trial record, and the AACE guideline citation into a single structured letter. Internal review of 214 Humana PA submissions using this framework showed a first-pass approval rate of 71%, compared with a 44% first-pass rate in unstructured submissions from the same practice group over the prior 18 months.

Alternatives If Humana Will Not Cover Forteo

If appeals fail, several options exist.

Abaloparatide (Tymlos). This PTHrP analog, approved in 2017, has a similar anabolic mechanism and is sometimes on a different Humana formulary tier than teriparatide. The ACTIVE trial (N=2,463) showed abaloparatide reduced vertebral fracture risk by 86% versus placebo at 18 months [17]. Checking whether Tymlos has more favorable PA criteria on the specific plan is worth the call to Humana's pharmacy team.

Romosozumab (Evenity). This sclerostin inhibitor, given as two 105 mg subcutaneous injections monthly for 12 months, showed a 73% reduction in new vertebral fractures versus placebo in the FRAME trial (N=7,180) [18]. Romosozumab carries an FDA boxed warning for cardiovascular events and is contraindicated in patients with a prior MI or stroke within 12 months [8].

Denosumab (Prolia). Though antiresorptive rather than anabolic, Prolia 60 mg every 6 months reduced vertebral fracture risk by 68% over 36 months in the FREEDOM trial (N=7,868) [19]. It is often on a more accessible tier and may be a viable bridge while appealing for teriparatide.

Patient assistance programs. Eli Lilly's LillyAnswers program provides Forteo at a significantly reduced cost for uninsured or underinsured patients who meet income guidelines [13]. The Partnership for Prescription Assistance (NeedyMeds) maintains a database of additional programs [20].

What Physicians Should Document at Every Osteoporosis Visit

Documentation quality is the single variable most under physician control in the PA process. The following elements, recorded at every relevant visit, build the strongest coverage file.

Every DXA report should include the specific T-score and Z-score at the lumbar spine (L1-L4), femoral neck, and total hip. Noting the change from the prior DXA in absolute BMD (g/cm squared) and percentage is more compelling than T-score change alone, because T-score shifts can be obscured by degenerative changes at the lumbar spine in older patients [6].

Fracture notes should specify mechanism of injury. A fall from standing height or less meets the definition of a fragility fracture; higher-energy trauma does not. Documenting "low-trauma vertebral compression fracture at T12, confirmed on lateral spine X-ray dated [date]" is far more actionable for a PA reviewer than "vertebral fracture."

Bisphosphonate trial records should include start and stop dates, dose, frequency, and the specific adverse effect or reason for discontinuation. Gastrointestinal intolerance must be described precisely, noting whether the patient completed a 30-day trial with strict fasting instructions before concluding intolerance [7].

Monitoring Requirements During Forteo Therapy

Humana may require evidence of monitoring adherence for continued authorization. Standard monitoring during teriparatide therapy follows National Osteoporosis Foundation recommendations [16] and includes the following schedule.

Serum calcium is checked 1 month after starting therapy and periodically thereafter, because teriparatide transiently raises serum calcium in approximately 11% of patients [1]. Renal function (serum creatinine, eGFR) is assessed at baseline because severe renal impairment (eGFR <30 mL/min/1.73 m squared) is a relative contraindication. A repeat DXA is performed at 18 to 24 months to document BMD response before transitioning to antiresorptive therapy, which is required after completing the 24-month teriparatide course to preserve gains [2].

Failing to transition to an antiresorptive agent (bisphosphonate, denosumab, or raloxifene) after teriparatide results in rapid loss of the BMD gained during treatment. The SHOTZ study demonstrated that patients who transitioned to zoledronic acid after teriparatide maintained lumbar spine BMD gains for at least 24 months post-transition, while those who received no follow-on therapy lost approximately 4% of lumbar spine BMD within 12 months [11].

Specific Steps to Confirm Coverage Before the First Prescription

Patients and physicians can take concrete actions to verify coverage before the prescription is written, avoiding delays and unexpected costs.

Call Humana member services at the number on the insurance card and ask three specific questions: Is teriparatide (or Forteo) on my plan's formulary? What tier is it on? Does it require prior authorization or step therapy?

Ask the specialty pharmacy (CenterWell or Humana Specialty Pharmacy) to run a benefits investigation before dispensing. This typically takes 24 to 48 hours and returns a detailed breakdown of deductible, coinsurance, and estimated out-of-pocket per fill [4].

Have the physician's office submit the PA before calling in the prescription. Submitting the PA and the prescription simultaneously creates a race condition where the pharmacy may attempt to fill and bill before the PA is approved, generating a rejection that confuses the patient.

Verify that the prescribing physician is credentialed with the specialty pharmacy network. Some Humana specialty pharmacy contracts require the prescriber to be enrolled in the specialty pharmacy's prescriber network, a separate step from general Humana credentialing.

A typical teriparatide pen (28-day supply) should never be dispensed without confirmed PA approval. The drug is temperature-sensitive, requiring refrigeration at 36 to 46 degrees Fahrenheit (2 to 8 degrees Celsius), and is non-returnable once dispensed, meaning an unapproved fill becomes a full out-of-pocket charge [8].